Technology

DiaMedica Therapeutics Inc. Common Stock

$8.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.37 (-4.39%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell DMAC and other stocks, options, and ETFs commission-free!

About DMAC

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN. The listed name for DMAC is DiaMedica Therapeutics Inc. Common Stock.

CEO
Rick John Pauls
Employees
9
Headquarters
Minneapolis, Minnesota
Founded
2000
Market Cap
142.59M
Price-Earnings Ratio
Dividend Yield
Average Volume
223.99K
High Today
$8.47
Low Today
$7.95
Open Price
$8.30
Volume
234.38K
52 Week High
$10.88
52 Week Low
$1.87

Collections

DMAC Earnings

-$0.21
-$0.14
-$0.07
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 22, After Hours

You May Also Like

MSADY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure